Intravenous IgG Reduces Pathogenic Autoantibodies, Serum IL-6 Levels, and Disease Severity in Experimental Bullous Pemphigoid Models

Sasaoka, Tetsumasa; Ujiie, Hideyuki; Nishie, Wataru; Iwata, Hiroaki; Ishikawa, Makoto; Higashino, Hiroshi; Natsuga, Ken; Shinkuma, Satoru; Shimizu, Hiroshi

Intravenous IgG Reduces Pathogenic Autoantibodies, Serum IL-6 Levels, and Disease Severity in Experimental Bullous Pemphigoid Models

Sasaoka, Tetsumasa; Ujiie, Hideyuki; Nishie, Wataru et al.

Journal of investigative dermatology, 2018, 138(6), 1260-1267

Permalink : https://hdl.handle.net/2115/74501

このアイテムのアクセス数:712件（2026-08-16 07:17 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
JInvestDermatol138_1260_suppl	pdf	120 KB	304	Supplementary Materials
JInvestDermatol138_1260	pdf	2.81 MB	527

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/74501
タイトル	Intravenous IgG Reduces Pathogenic Autoantibodies, Serum IL-6 Levels, and Disease Severity in Experimental Bullous Pemphigoid Models
その他のタイトル	Intravenous immunoglobulin reduces pathogenic autoantibodies, serum IL-6 levels and disease severity in experimental bullous pemphigoid models
その他のタイトル	IVIG reduces disease severity in experimental BP
著者	Sasaoka, Tetsumasa ; Ujiie, Hideyuki ; Nishie, Wataru ; Iwata, Hiroaki ; Ishikawa, Makoto ; Higashino, Hiroshi ; Natsuga, Ken ; Shinkuma, Satoru ; Shimizu, Hiroshi
著者名 Sasaoka, Tetsumasa
e-Rad_Researcher 60374435 著者名 Ujiie, Hideyuki
e-Rad_Researcher 20443955 著者名 Nishie, Wataru
e-Rad_Researcher 20397334 著者名 Iwata, Hiroaki
著者名 Ishikawa, Makoto
著者名 Higashino, Hiroshi
e-Rad_Researcher 70645457 著者名 Natsuga, Ken
e-Rad_Researcher 00613788 著者名 Shinkuma, Satoru
e-Rad_Researcher 00146672 著者名 Shimizu, Hiroshi
言語	英語
発行日	2018-06
出版者	Elsevier
収録物名	Journal of investigative dermatology
巻(号)	138(6)
ページ	1260-1267
抄録	Bullous pemphigoid (BP) is an autoimmune blistering disease characterized by autoantibodies to COL17. Currently, systemic corticosteroids are used as first-line treatments for BP; alternatively, intravenous administration of high-dose IgG (IVIG) has been shown to be effective for patients with steroid-resistant BP in clinical practice. However, the effect of IVIG on BP has not fully been investigated. To examine the effects and mechanisms of action of IVIG against BP, we performed IVIG experiments using two experimental BP mouse models. One is a passive-transfer BP model that reproduces subepidermal separation in neonatal mice by the passive transfer of IgGs against COL17, such as polyclonal or monoclonal mouse IgG or IgG from BP patients. The other is an active BP model that continuously develops a disease phenotype in adult mice. IVIG decreased pathogenic IgG and the disease scores in both models. Injected IVIG distributed throughout the dermis and the intercellular space of the lower epidermis. Notably, IVIG inhibited the increase of IL-6 in both models, possibly by suppressing the production of IL-6 by keratinocytes. These results suggest that the inhibitory effects of IVIG on BP are associated with the reduction of pathogenic IgG and the modulation of cytokine production.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
権利情報	© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
PISSN	0022-202X
関連情報	PMID 29391250
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1016/j.jid.2018.01.005